AcuCort AB (Spotlight Stock Market: ACUC) announces that the Board of Directors and the CEO have subscribed for options to purchase shares in the company according to a resolution at the 2021 Annual General Meeting.
The CEO has subscribed for options that provide the opportunity to subscribe for 133,336 shares, the Chairman of the Board 88,888 shares and all four Board members 44,444 shares each. Subscription of shares in AcuCort AB (publ) may take place during the period from April 1, 2023, to June 30, 2023, at a price of 9.62 SEK per share.
The information was submitted for publication, through the agency of the contact person below, on August 11, 2021.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.